148OPhase III evaluating the addition of fulvestrant (F) to anastrozol (A) as adjuvant therapy in postmenopausal women with hormone receptor positive HER2 negative (HR+/HER2-) early breast cancer (EBC): Results from the GEICAM/2006-10 study
Ruiz-Borrego, M., Martin Jimenez, M., Ruiz, A., Lluch, A., Ramos, M., Cruz Jurado, J., Baena-Canada, J.M., Cirauqui, B., Rodriguez-Lescure, A., Alba Conejo, E., Martínez Jañez, N., Muñoz, M., Antolin,Volume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx362
Date:
September, 2017
File:
PDF, 75 KB
english, 2017